

Division of Cancer Treatment and Diagnosis (DCTD)

Pushpa Tandon, Ph.D.

*Program Director, Division of Cancer Treatment and Diagnosis, NCI
Cancer Imaging Program*

NCI Organizational Structure

Extramural

Division of Cancer
Biology

Division of Cancer
Control and
Population
Sciences

Division of
Cancer
prevention

Division of
Extramural
activities

Division of Cancer
Treatment and
Diagnosis

Intramural

Center for Cancer
Research

Division of Cancer
Epidemiology and
Genetics

Division of Cancer Treatment and Diagnosis (DCTD)

➤ Cancer Imaging Program

➤ Cancer Diagnosis Program

➤ Cancer Therapy Evaluation Program

➤ Radiation Research Program

➤ Biometric research Program

➤ Development Therapeutics Program

➤ Translational Research Program

➤ Office of Cancer Complementary and Alternative Medicine

➤ Office of Cancer Clinical Proteomics Research

Diagnosis and Treatment

- Cancer Biology
- Molecular Imaging
- Nanotechnology
- Target identification,
- Drug development
- Clinical trials
- Technology development
- Biobanks, genomic, proteomic and imaging archives
- Imaging: diagnosis, treatment planning; radiation therapy treatment evaluation
- Information Technologies
 - Artificial Intelligence
 - Algorithm development
 - Machine learning
 - Treatment Planning
 - Predictive analysis
 - Robotics

DCTD: Major Activities

Experimental
Therapeutics Clinical
Trial Network (ETCTN)

National Clinical Trials
Network (NCTN)

Specialized Programs
of Research Excellence
(SPORE)

NCI Experimental
Therapeutics (NExT)
Program

NCI Formulary

NCI Patient-Derived
Models Repository
(PDMR)

NCTN/NCORP Data
Archive

NCTN Navigator

Quantitative Imaging
Network (QIN)

Co-Clinical Imaging
Resources Program
(CIRM)

Cancer Moonshot:
Biobank

Research Resources

DCTD has a variety of resources available for preclinical and clinical anti-cancer drug development, as well as resources pertinent to clinical applications of imaging.

Biomarkers

Biometric Research

Cancer Diagnosis Research

Clinical Proteogenomics

Clinical Trials

Drug Discovery & Development

Imaging

Radiation Research

<https://dctd.cancer.gov/ResearchResources/default.htm>

COVID-19 Research Initiatives


- **NCI COVID-19 in Cancer Patients study (NCCAPS):** involves all clinical trial programs
- **NCI COVID-19 Serology Program:** understand immune response to SARS-CoV-2 (SeroNet)
- **Study of Other Risk Factors:** (smoking status in COVID patients related to severity)
- **Search for COVID 19-Treatments:** (RAS initiative: compounds that block RAS protein that drive tumor growth)
- **Digital Health Solutions:** To address the COVID-19 (pandemic (Along with NIBIB)
- **Genomic Studies of COVID-19 Outcomes- (DCEG)**
- <https://www.cancer.gov/research/key-initiatives/covid-19>



The Cancer Imaging Archive posts COVID-19 imaging data to benefit community

The Frederick National Lab (FNL) has published an article about TCIA's COVID-19 response efforts!

“Publicly available datasets related to COVID-19 are appearing in an unexpected place—the Cancer Imaging Archive (TCIA), a project of the Division of Cancer Treatment and Diagnosis of the National Cancer Institute.



Since the start of the pandemic, researchers around the world have been racing to learn as much as possible about the virus—how it spreads, how to diagnose and treat it, and how to develop vaccines against it. One way to help speed up scientific discovery is data sharing.”

Read the full article [here](#) and find the COVID Collections available on TCIA [here](#).

FNL newsletter
February 2021 by Justin Kirby

NEW

VIEW THE

COVID-19
CORONAVIRUS

COLLECTION

CIP: Focus Areas and Funding Support

The Cancer Imaging Archives (TCIA)

Co-Clinical Imaging Research Resource Program (CIRP)

Nanotechnology: NCI Alliance for Nanotechnology in Cancer

Quantitative Imaging Network (QIN)

Information Technologies for Cancer Research (ITCR)

Investigator initiated R01 grant

Small Business grants and contracts (SBIR/STTR)

Radiation Research Program (RRP)


Funding Opportunities

RRP Initiatives (current)

FOA #	Initiative Title
RFA-CA-22-046	Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
NOT-CA-22-113	Notice of Intent to Publish a Funding Opportunity Announcement for Radiation Oncology-Biology Integration Network (ROBIN) Centers (U54 Clinical Trial Required)
PAR-22-198	Precision Approaches in Radiation Synthetic Combinations (PAIRS, R01 Clinical Trial Optional)
PAR-22-199	Precision Approaches in Radiation Synthetic Combinations (PAIRS, R21 Clinical Trial Optional)
PAR-22-139	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed)
PAR-22-140	Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed)

Guidance for NCI Clinical Trial Activities Affected by the Novel Coronavirus

[More...](#)



NCI National Clinical Trials Network

a National Cancer Institute program

NCTN Overview


NCI transformed its longstanding Cooperative Group Program into the new NCI National Clinical Trials Network (NCTN) Program. [More...](#)

**Cancer Therapy Evaluation Program
Early Drug Development**



How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find Out.

[More...](#)



NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)

is a phase 2 clinical trial for children and adolescents with advanced solid tumors – including non-Hodgkin lymphomas, brain tumors, and histiocytoses – that have not responded to treatment or have progressed on standard therapy. [More...](#)



Experimental Trials Network

The National Cancer Institute is leading the way in the pharmaceutical industry in testing individual investigational drugs and innovative cancer therapies through the Experimental Clinical Trials Network. These therapies use an inclusive team-based approach.



CDP
Improve the
diagnosis and
assessment of
cancer

The screenshot shows the homepage of the GTEX Biobank website. At the top is a navigation menu with links for Home, About CDP, Scientific Programs, Funding Opportunities, Resources, and News and Publications. The main banner features a woman in a white lab coat looking through a microscope, with the text "WELCOME To The GTEX Biobank" overlaid. Below the banner are four buttons: Funding Opportunities, GTEX Biobank, NCTN Navigator, and Clinical Trial Applications. A central text box titled "Welcome to the Cancer Diagnosis Program!" describes the program's mission to improve cancer diagnosis and assessment. On the right side, there is a "Quick Links" section with several links to various resources and documents. At the bottom left, a browser address bar shows the URL "s://biospecimens.cancer.gov/gtexbiobank/".

Home About CDP Scientific Programs Funding Opportunities Resources News and Publications

WELCOME
To The GTEX Biobank

Funding Opportunities GTEX Biobank NCTN Navigator Clinical Trial Applications

Welcome to the Cancer Diagnosis Program!

The Cancer Diagnosis Program strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This national program stimulates, coordinates and funds resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens in order to better characterize cancers and allow improved medical decision making and evaluation of response to treatment.

For more information about the Cancer Diagnosis Program and its Branches, please click [here](#).

Quick Links


- [The NCI Grants Process](#)
- [Templates for Clinical Assay Development](#)
- [Biorepositories and Biospecimen Research Branch](#)
- ["Omics" Checklist — Criteria For Use of Omics-based Predictors in Clinical Trials](#)
- [Ethical, Legal and Social Implications of Biobanking in Cancer Research](#)
- [NCI-MATCH/EAY131](#)
- [Reporting Recommendations for Tumor Marker Prognostic Studies \(REMARK\)](#)

Stay Connected

s://biospecimens.cancer.gov/gtexbiobank/

Developmental Therapeutics Program (DTP)

The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents



Funding Opportunity Announcement:

- [Assay development and screening for discovery of chemical probes, drugs or immunomodulators \(R01 Clinical Trial Not Allowed\)](#)
- [Notice of Special Interest \(NOSI\): Advancing the development of tumor site-activated small molecules](#)
- [NCI Clinical and Translational Exploratory/Developmental Studies \(R21 Clinical Trial Optional\)](#)

(DCTD) Tumor Repository



Research to Investigate

PRINCIPAL INVESTIGATOR: Steven Paterno, PhD, deputy director of the Duke Cancer Institute

PROJECTS SUPPORTED BY THE P20 SPORE:

- Lung cancer disparities, led by Jennifer Freedman, PhD, and Jeffrey Clarke, MD
- Stomach cancer disparities, led by Melina Epplein, PhD, and Katherine Garman, MD

disciplinary program of ...

ational Institutes

Translational Research Program (TRP)



NCI Specialized Programs of Research Excellence (SPORE)


Translational Research Program (TRP)
 Division of Cancer Treatment and Diagnosis (DCTD)
 National Cancer Institute (NCI)
 National Institutes of Health (NIH)
 Website: trp.cancer.gov

Peter Ujhazy, MD, PhD
 2018 NCI IMAT PI Meeting


Office of Cancer Complementary and Alternative Medicine (OCAM)

Established in October 1998 to coordinate and enhance the activities of the National Cancer Institute (NCI) in the arena of complementary and alternative medicine (CAM)



International Activities:
Chinese Medicine
Indian Medicine
Research Resources



Microbial-based Cancer Therapy - Bugs as Drugs



Technologies to Overcome Cancer



Annual Integrative Women's Health Symposium 2022

View Videocast – Traditional Medicines for COVID-19 and Cancer: Effects on Immunity and Inflammation


Integrative Oncology: Addressing the Global Challenges of Cancer Prevention and Treatment

The National Cancer Institute Cannabis, Cannabinoids, and Cancer Research Symposium videos

The NCI Library of TCM Plant Extracts


New Funding Opportunity: Microbial-based Cancer Therapy – Bugs as Drugs

Publicly Available Research Resources




NCI
Research Resource
ROADMAPS Dataset
Responses to Oncology
Agents and Dosing in Models
to Aid Preclinical Studies

The image shows a screenshot of a web page with a table of research resources. The table has columns for 'Drug Name', 'Doses Tested', 'Model System', 'Admin Route', 'Dosing Schedule', and 'Response'. The text 'NCI Research Resource ROADMAPS Dataset' is overlaid on the table. Below the table, the text 'Responses to Oncology Agents and Dosing in Models to Aid Preclinical Studies' is visible.



NCI WORKSHOP
Neutron Capture Therapy
for Cancer
April 20-22, 2022
Important updates on the new phase of NCT
Workshop Summary &
Recordings Available

The image is a promotional graphic for an NCI workshop. It features a central text box with a light background and a blue border. The text inside the box reads: 'NCI WORKSHOP Neutron Capture Therapy for Cancer April 20-22, 2022 Important updates on the new phase of NCT'. Below the box, it says 'Workshop Summary & Recordings Available'. The background is a dark blue with faint atomic symbols.



Novel Chemical Approaches for Targeting Fusion Oncoproteins
Webinar Series: Fridays, 12:00 - 1:00 pm ET (Aug. 19 - Oct. 21, 2022)

The image is a promotional graphic for a webinar series. It features a central text box with a light background and a blue border. The text inside the box reads: 'Novel Chemical Approaches for Targeting Fusion Oncoproteins Webinar Series: Fridays, 12:00 - 1:00 pm ET (Aug. 19 - Oct. 21, 2022)'. Below the box, there are four images: a protein structure, a group of people, a chemical structure, and a pile of pills.

Publicly Available Research Resources

Frederic National Lab for Cancer Research

The only national laboratory dedicated to the biomedical sciences

Biomedical Imaging

Cancer Research

Clinical Research

Data Science

Drug Development

Immunology

Molecular Biology

Pathology

Research Technology

Virology

Genetics

HIV/AIDS Research

Funding Opportunities

DCTD Programs

Trans-DCTD

Trans-NCI

Trans-NIH

<https://dctd.cancer.gov/FundingPartnerships/PAsRFAs.htm>

Workforce and Career Development

Diversity Career Development Program:

NCI is committed to excellence in science and to fostering a diverse and inclusive workforce. The Diversity Career Development Program (DCDP) seeks to empower talented intramural postdoctoral trainees, including but not limited to those from underrepresented groups in biomedical research, to achieve their full potential at NCI.

NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required)

<https://grants.nih.gov/grants/guide/pa-files/PAR-21-302.html>

NCI Equity and Inclusion Program



About the Program



**News & Updates
on Health Equity**



**Equity Council &
Working Groups**

Funding Opportunities to promote workforce diversity

<https://www.cancer.gov/research/key-initiatives/nci-equity-inclusion-program/funding>

DCTD Newsletters:

<https://dctd.cancer.gov/NewsEvents/News-2022.htm>

Questions??